Moderna's stock continues to edge lower after vaccine skepticism is voiced
Moderna's stock continues to edge lower after vaccine skepticism is voiced
MarketWatch
0 shares
1 views
You might like
Related news coverage
Morgan Stanley now sees Moderna shares spiking 26% from current levels, cites 65% chance of success for virus vaccine (MRNA)
Business Insider
**
· *Morgan Stanley raised its Moderna price target to $90 from $37, citing "initial promising Covid-19 vaccine data,"..
-
Moderna hit by criticism over lack of data on coronavirus vaccine candidate results
Proactive Investors
-
Asian shares mixed as virus worries counter recovery hopes
SeattlePI.com
-
Asian Markets Mostly Lower
RTTNews
-
Goldman Sachs says stocks will tumble 18% in the next 3 months — and lays out 6 risks it thinks investors are ignoring
Business Insider
Advertisement
More coverage
Goldman Sachs warns stocks will tumble 18% in the next 3 months — and lays out 6 risks it thinks investors are ignoring
· *Goldman Sachs expects the S&P 500 to close the year 2% higher, but not before enduring an 18% plunge over the next three..
Business Insider
Nasdaq erases losses for 2020 as mega-cap tech rallies offset coronavirus drag
· *The Nasdaq composite turned positive for the year-to-date on Thursday as major tech names fuel a rapid recovery.*
· *The..
Business Insider